Latest Breaking News On - Auron therapeutics - Page 1 : comparemela.com

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavid millanAuron therapeutics incMonique allairethrust strategic communicationsAmerican association for cancer researchRyan flinnthrust strategic communicationsAmerican associationCancer researchKate yenAuron therapeutics

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph D and Christopher Guiffre, J D , MBA

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph D and Christopher Guiffre, J D , MBA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristopher guiffreEntact bioCubist pharmaceuticals incBabson collegeHydra biosciences incUniversity of nebraska medical centerUniversity of vermontAlvos therapeutics incAton pharmaceuticalsBoston college carroll school of managementAuron therapeutics incMonique allairethrust strategic communicationsBoston college law schoolKate yenRibon therapeutics

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph D and Christopher Guiffre, J D , MBA

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph D and Christopher Guiffre, J D , MBA
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesMonique allaireVicky richonEntact bioChristopher guiffreAton pharmaceuticalsAlvos therapeutics incHydra biosciences incUniversity of vermontBoston college law schoolUniversity of nebraska medical centerCubist pharmaceuticals incBabson collegeStrategic communicationsBoston college carroll school of managementChris guiffre appointed president

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph D and Christopher Guiffre, J D , MBA

United statesChristopher guiffreMonique allaireEntact bioVicky richonBabson collegeStrategic communicationsCubist pharmaceuticals incBoston college carroll school of managementHydra biosciences incAlvos therapeutics incAton pharmaceuticalsBoston college law schoolUniversity of vermontUniversity of nebraska medical centerChris guiffre appointed president

Benefits of ivosidenib regimen for IDH1 -mutant AML increase with longer follow-up

CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.The long-term follow-up data, presented at ASCO Annual Meeting, showed an additional 5-month increase in median OS with the ivosidenib (Tibsovo, Servier)

United statesAstellas amgen biopharamaMindy valcarcelBydevin mclaughlinBristol myers squibbGustave roussy cancer centerJazz pharmaceuticalsAmgen biopharamaAuron therapeuticsForma therapeuticsLoxo oncologyRemix therapeutics